Trial record 16 of 846 for:    osteoporosis AND (woman OR women OR female)

STEP: Study of Imaging Techniques (ImaTx and DXA) in Postmenopausal Women With OstEoporosis Using Preotact (FP-008-ES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00583518
Recruitment Status : Completed
First Posted : December 31, 2007
Last Update Posted : May 7, 2012
Information provided by (Responsible Party):

Brief Summary:
The primary objective of the study is to explore the relationship between a new image technology (ImaTx), that analyzes the trabecular structure of the bone using digitized radiographs and the bone mineral density (BMD) measured by Dual X-ray Absorptiometry (DXA) in the lumbar spine of postmenopausal (PM) women with osteoporosis (OP) after treatment with PTH (1-84).

Condition or disease Intervention/treatment Phase
Postmenopausal Women With Primary Osteoporosis Drug: Parathyroid hormone (PTH) Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 129 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label, Multi-centre, Longitudinal, Prospective, Phase IV Clinical Trial to Compare Two Image Technologies (ImaTx and DXA) Assessing the Anabolic Effects of PTH(1-84) in Postmenopausal Women With Primary Osteoporosis
Study Start Date : November 2007
Actual Primary Completion Date : November 2011
Actual Study Completion Date : February 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoporosis

Intervention Details:
  • Drug: Parathyroid hormone (PTH)
    Postmenopausal women with primary osteoporosis
    Other Name: Preotact

Primary Outcome Measures :
  1. Correlation coefficient between the percentage of increase in Bone Mineral Density (BMD) obtained by DXA in the lumbar spine and in Trabecular Fragment Length (TFL) obtained by ImaTx in digitised radiographs of lumbar spine from baseline to EOT [ Time Frame: 72 weeks ]

Secondary Outcome Measures :
  1. BMD obtained by DXA in the lumbar spine (DXA SPI BMD). Two measurements will be determined: Mean value (g/cm2) and percentage of increase at EOT versus baseline (%). [ Time Frame: 72 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Has the subject given informed consent according to local requirements before any trial-related activities? A trial-related activity is any procedure that would not have been performed during the routine management of the subject.
  2. Is the subject a female?
  3. Is the subject 65 years old or above?
  4. Is the subject postmenopausal (more than 5 years), in the judgement of the investigator?
  5. Does the subject have primary osteoporosis, with a lumbar spine T score ≤ -3.0 SD, or a lumbar spine T-score ≤ -2.5 SD and previous fragility fracture[1], with a minimum of two evaluable lumbar vertebrae?
  6. Does the subject have a life expectancy of > 2 years?
  7. Does the subject have a clinical indication to receive PTH(1-84) and is able to self-inject (or to have PTH(1-84) injection by a helper)?

All inclusion criteria must be answered "yes" for a subject to participate in the trial.

[1] Definition of fragility fracture in the scope of the study: Bone fractures that occur as a result of a fall from standing height or less. That is, fractures resulting from mechanical forces that would not ordinarily cause fractures in a healthy person.

Exclusion Criteria:

  1. Is the patient currently taking any of the following treatments: bisphosphonates, selective estrogen receptor modulators or hormone replacement therapy (if the patient discontinues any of these treatments at the screening visit, the question can be answered NO and the patient can be included)?
  2. Has the subject received, during her lifetime, strontium, fluoride or calcitonin > 3 months in total?
  3. Has the subject ever been treated with teriparatide or PTH(1-84)?
  4. Is the subject taking any other medication known to affect bone metabolism in the opinion of the investigator?
  5. Has the subject ever received radiation therapy to the skeleton?
  6. Has the subject ever been treated for a bone malignant disease?
  7. Is the subject suffering from any known clinically significant diseases affecting calcium metabolism, including metabolic bone diseases such as hyperparathyroidism, Paget's disease, osteogenesis imperfecta, or osteomalacia?
  8. Does the subject have any known history of hypersensitivity to parathyroid hormone or any of the excipients in the drug?
  9. Does the subject have an elevated serum calcium (total serum calcium value >10.2 mg/dl) after at least 14 days of a 1000 mg calcium and 800 IU vitamin D3 supplementation?
  10. Does the subject have a clinically significant elevation of serum alkaline phosphatase judged by the investigator?
  11. Does the subject have an impaired kidney function with creatinine clearance <30ml/min (indirect measurement by serum creatinine)?
  12. Does the subject have a severe hepatic impairment, defined as > 9 Child-Pugh score?
  13. Has the subject participated in a clinical trial with an Investigational Medicinal Product (IMP) during the last 30 days?
  14. Does the subject have a bilateral hip replacement?

All exclusion criteria must be answered "no" for a subject to participate in the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00583518

Roskilde, Denmark, 4000
Sponsors and Collaborators
Study Chair: Nycomed Clinical Trial Operations Headquaters

Responsible Party: Nycomed Identifier: NCT00583518     History of Changes
Other Study ID Numbers: FP-008-ES
First Posted: December 31, 2007    Key Record Dates
Last Update Posted: May 7, 2012
Last Verified: May 2012

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs